Companies: 49,246 Total Market Cap: 132578865767700.31

Alvotech

NASDAQ: ALVO
Healthcare Drug Manufacturers - Specialty & Generic
Rank #4682
Market Cap 2.95 B
Volume 166,025
Price 9.79
Change (%) 2.83%
Country or region Luxembourg Luxembourg

Alvotech's latest marketcap:

2.95 B

As of 05/20/2025, Alvotech's market capitalization has reached $2.95 B. According to our data, Alvotech is the 4682th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 2.95 B
Revenue (ttm) 587.89 M
Net Income (ttm) 96.55 M
Shares Out 301.81 M
EPS (ttm) 0.34
Forward PE 29.29
Ex-Dividend Date n/a
Earnings Date 05/07/2025
Market Cap Chart
Data Updated: 05/20/2025

Alvotech's yearly market capitalization.

Alvotech has seen its market value grow from $327.81 M to $2.95 B since 2020, representing a total increase of 800.87% and an annual compound growth rate (CAGR) of 65.07%.
Date Market Cap Change (%)
05/20/2025 $2.95 B -26.79%
12/31/2024 $3.99 B 30.92%
12/29/2023 $3.05 B 22.59%
12/30/2022 $2.49 B 705.34%
12/31/2021 $308.75 M -5.82%
12/31/2020 $327.81 M

Company Profile

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. The company specializes in biosimilar products targeting autoimmune, eye, and bone disorders, as well as cancer.

Key Biosimilar Products

  • AVT02 – A high-concentration biosimilar to Humira, treating inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and plaque psoriasis.
  • AVT04 – A biosimilar to Stelara, addressing psoriatic arthritis, ulcerative colitis, and other inflammatory disorders.
  • AVT06 – A biosimilar to Eylea, used for age-related macular degeneration, diabetic retinopathy, and macular edema.
  • AVT03 – A biosimilar to Xgeva and Prolia, aiding in bone fracture prevention and cancer-related bone conditions.
  • AVT05 – A biosimilar to Simponi and Simponi Aria, treating rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
  • AVT16 – A biosimilar to Entyvio, targeting moderate to severe ulcerative colitis and Crohn’s disease.
  • AVT23 – A biosimilar to Xolair, addressing allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyps.
  • AVT33 – A biosimilar to Keytruda, currently in early-phase development.

Founded in 2013, Alvotech is headquartered in Luxembourg, Luxembourg.

Frequently Asked Questions

As of 05/20/2025, Alvotech (including the parent company, if applicable) has an estimated market capitalization of $2.95 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Alvotech global market capitalization ranking is approximately 4682 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Luxembourg
Founded 2013
IPO Date n/a
Employees 1,012
CEO Robert Wessman
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Address 9, Rue de Bitbourg
Luxembourg, 1273
Luxembourg
Website https://www.alvotech.com
People Also Watch
Zoetis
163.65 2.83%
Merck KGaA
132.21 2.83%
Haleon plc
547.42 2.83%
NSE-SUNPHARMA
19.96 2.83%